Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma.
Veronica RendoEudocia Quant LeeConnor BossiNicholas KhuuMichelle A RudekSangita PalAbigail R N ReynoldsAuriole C R FassinouGeorges AyoubEmily LapinskasWilliam PisanoJohn JeangSylwia A StopkaMichael S ReganJohan SpetzArati DesaiFrank LiebermanJoy D FisherKristine PeltonRaymond Y HuangLouis B NaborsMatthias HoldhoffNeeraja DandaRoy StrowdSerena DesideriTobias WalbertXiaobu YeNathalie Y R AgarStuart A GrossmanBrian M AlexanderPatrick Y WenKeith L LigonRameen BeroukhimPublished in: medRxiv : the preprint server for health sciences (2024)
Tissue sampling during this clinical trial allowed us to assess mechanisms of response and resistance associated with navtemadlin treatment in recurrent GBM. We report that clinically achievable doses of navtemadlin induce pharmacodynamic effects in tumor tissue, and suggest combinations with standard-of-care chemotherapy for durable clinical benefit.